Notizia - Recent Pharma, Healthcare and Biotech Happenings

Astellas’ Ophthalmology Innovation to Strengthen Further With Quethera Acquisition Astellas has acquired Quethera, a gene therapy company headquartered in the UK, which is focused on developing novel treatments for ocular disorders, such as glaucoma. Through this transaction, Astellas has acquired Quethera’s ophthalmic gene therapy program, which uses a recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal cells for the treatment of glaucoma. The lead pre-clinical candidate of the program has demonstrated significantly improved survival of retinal ganglion cells (RGCs) in pre-clinical models. Under the term...